Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1999-04-06
2001-01-30
Henley, III, Raymond (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S374100
Reexamination Certificate
active
06180656
ABSTRACT:
The present invention relates to the new use of 1-benzyl-3-(substituted hetaryl)-fused pyrazole derivatives, some of which are known, as medicaments, and to new active compounds, in particular to their use as vasodilators, if appropriate in combination with organic nitrates and NO donors and if appropriate in combination with compounds which inhibit the degradation of cGMP.
It is already known that 1-benzyl-3-(substituted hetaryl)-fused pyrazole derivatives inhibit stimulated platelet aggregation in vitro (cf. EP-667 345 A1; C. -C. Wu et al., Br. J. Pharmacol. 1995; 116: 1973-1978; F. -N. Ko et al., Blood 1994; 84: 4226-4233; S. -U. Yu et al., Blood 1996, 87: 3758-3767).
It has now surprisingly been found that 1-benzyl-3-(substituted hetaryl)-fused pyrazole derivatives of the general formula (I)
in which
R
1
represents hydrogen, halogen, hydroxyl or C
1
-C
3
-alkyl or C
1
-C
3
-alkoxy,
R
2
represents a radical of the formula
in which
R
5
denotes hydrogen, halogen, carboxyl, C
1
-C
3
-alkyl, C
1
-C
3
-alkoxy carbonyl or a radical of the formula —CH
2
—OR
6
,
in which
R
6
denotes hydrogen or C
1
-C
3
-alkyl,
R
3
and R
4
together form a radical of the formula
in which
R
7
denotes hydrogen, halogen, hydroxyl, C
1
-C
3
-alkyl or C
1
-C
3
-alkoxy,
and their isomeric forms and salts,
besides their weak antiaggregatory properties exhibit a marked vasodilatory action, in particular a lowering of blood pressure. They are thus suitable for the treatment of specific disorders of the cardiovascular system, in particular for the treatment of various forms of angina pectoris, of myocardial infarct, of cardiac insufficiency, of arteriosclerosis, stroke and of hypertension.
The compounds of the general formula (I) according to the invention can also be present in the form of their salts. In general, salts with organic or inorganic bases or acids may be mentioned here.
In the context of the present invention, physiologically acceptable salts are preferred. Physiologically acceptable salts can be salts of the substances according to the invention with mineral acids, carboxylic acids or sulphonic acids. Particularly preferred salts are, for example, those with hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid, naphthalenedisulphonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid or benzoic acid.
Physiologically acceptable salts can likewise be metal or ammonium salts of the compounds according to the invention if they have a free carboxyl group. Particularly preferred salts are, for example, sodium, potassium, magnesium or calcium salts, and also ammonium salts which are derived from ammonia, or organic amines such as, for example, ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine or ethylenediamine.
In the context of the invention, C
1
-C
3
-alkyl represents a straight-chain or branched hydrocarbon radical having 1 to 3 carbon atoms. Examples which may be mentioned are: methyl, ethyl, propyl and isopropyl.
In the context of the invention, C
1
-C
3
-alkoxy represents a straight-chain or branched alkoxy radical having 1 to 3 carbon atoms. Examples which may be mentioned are: methoxy, ethoxy, propoxy and isopropoxy.
In the context of the invention, C
1
-C
3
-alkoxycarbonyl represents a straight-chain or branched alkoxycarbonyl radical having 1 to 3 carbon atoms. Examples which may be mentioned are: methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl and isopropoxycarbonyl.
Preferably, compounds of the general formula (I) according to the invention
in which
R
1
represents hydrogen, fluorine, chlorine, C
1
-C
3
-alkyl or C
1
-C
3
-alkoxy,
R
2
represents a radical of the formula
in which
R
5
denotes hydrogen, chlorine, carboxyl, C
1
-C
3
-alkyl, C
1
-C
3
-alkoxycarbonyl or a radical of the formula —CH
2
—OR
6
,
in which
R
6
denotes hydrogen or methyl,
R
3
and R
4
together form a radical of the formula
in which
R
7
denotes hydrogen, fluorine, chlorine, C
1
-C
3
-alkyl or C
1
-C
3
-alkoxy, and their isomeric forms and salts,
are used for the treatment of specific cardiovascular disorders.
Particularly preferably, compounds of the general formula (I) according to the invention
in which
R
1
represents hydrogen, fluorine, chlorine or methoxy,
R
2
represents a radical of the formula
in which
R
5
denotes hydrogen, C
1
-C
3
-alkyl or a radical of the formula —CH
2
—OR
6
,
in which
R
6
denotes hydrogen or methyl,
R
3
and R
4
together form a radical of the formula
in which
R
7
denotes hydrogen, chlorine, fluorine, methyl or methoxy, and their isomeric forms and salts,
are used for the treatment of specific cardiovascular disorders.
The invention additionally relates to new substances which are listed in the following table:
TABLE
The known and new compounds of the general formula (I) according to the invention can be prepared by customary methods, e.g. according to EP-667 345 A1.
Moreover, the invention preferably also includes the combination of the compounds of the general formula (I) according to the invention and of the new substances with organic nitrates and NO donors.
Organic nitrates and NO donors in the context of the invention are in general substances which display their therapeutic action via the release of NO or NO species. Sodium nitroprusside (SNP), nitroglycerine, isosorbide dinitrate, isosorbide mononitrate, molsidomine and SIN-1 and similar substances are preferred.
The invention additionally includes the combination with compounds which inhibit the degradation of cyclic guanosine monophosphate (cGMP). These are in particular inhibitors of the phosphodiesterases 1, 2 and 5; nomenclature according to Beavo and Reifsnyder (1990) TIPS 11 pp. 150-155. By means of these inhibitors, the action of the compounds according to the invention is potentiated and the desired pharmacological effect is increased.
The new and known compounds of the general formula (I) to be used according to the invention exhibit an unforeseeable, valuable spectrum of pharmacological action. They induce, for example, a vasorelaxation and lead to a lowering of blood pressure and increase in the coronary blood flow.
They are thus suitable for use in the treatment of specific disorders of the cardiovascular system such as, for example, the various forms of angina pectoris, of myocardial infarct, of cardiac insufficiency, of arteriosclerosis, stroke and of hypertension.
To determine the cardiovascular action, the following investigations were carried out: in in vitro investigations on cells of vascular origin, the influence on guanylate cyclase-dependent cGMP formation was tested with and without NO donors. The vasorelaxant action was determined on rabbit aorta rings precontracted with phenylephrine. The hypotensive action was investigated in anaesthetized rats.
Stimulation of Soluble Guanylate Cyclase in Primary Endothelial Cells
Primary endothelial cells were isolated from pig aortas by treatment with collagenase soln. The cells were then cultured in culture medium until confluence was achieved. For the investigations, the cells were passaged, inoculated into cell culture plates and subcultured until confluence was achieved. To stimulate the endothelial guanylate cyclase, the culture medium was aspirated and the cells were washed once with Ringer's solution and incubated in stimulation buffer with or without NO donor (sodium nitroprusside, SNP, 1 &mgr;M). Following this, the test substances (final concentration 1 &mgr;M) were then pipetted onto the cells. After the end of the incubation time of 10 minutes, the buffer solution was aspirated and the cells were lysed at −20° C. for 16 hours. The intracellular cGMP was then determined radioimmunologically.
TABLE A
Ex No.
% cGMP increase (NOSYNTH)
1
>1000
2
72
3
250
4
413
7
734
8
28
10
238&ensp
Dembowsky Klaus
Feurer Achim
F{umlaut over (u)}rstner Chantal
H{umlaut over (u)}tter Joachim
Jaetsch Thomas
Bayer Aktiengesellschaft
Henley III Raymond
Norris McLaughlin & Marcus P.A.
LandOfFree
Use of condensated (hetaryl-substituted) 1-benzal-3-pyrazol... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of condensated (hetaryl-substituted) 1-benzal-3-pyrazol..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of condensated (hetaryl-substituted) 1-benzal-3-pyrazol... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2494265